In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Avadel Pharmaceuticals plc (NASDAQ: AVDL) closed at $15.0 down -1.77% from its previous closing price of $15.27. In other words, the price has decreased by -$1.77 from its previous closing price. On the day, 1.04 million shares were traded. AVDL stock price reached its highest trading level at $15.4465 during the session, while it also had its lowest trading level at $14.9.
Ratios:
For a deeper understanding of Avadel Pharmaceuticals plc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 17.86 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 247.28. For the most recent quarter (mrq), Quick Ratio is recorded 2.38 and its Current Ratio is at 2.79. In the meantime, Its Debt-to-Equity ratio is 0.42 whereas as Long-Term Debt/Eq ratio is at 0.41.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Wells Fargo on September 03, 2025, initiated with a Equal Weight rating and assigned the stock a target price of $16.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $12.Deutsche Bank initiated its Buy rating on February 11, 2025, with a $12 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 21 ’25 when Palczuk Linda bought 5,000 shares for $7.93 per share. The transaction valued at 39,640 led to the insider holds 67,900 shares of the business.
Thornton Peter J. bought 10,000 shares of AVDL for $80,450 on Jan 13 ’25. The Director now owns 104,055 shares after completing the transaction at $8.04 per share. On Jan 13 ’25, another insider, Ende Eric J, who serves as the Director of the company, bought 30,000 shares for $7.84 each. As a result, the insider paid 235,218 and bolstered with 208,900 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AVDL now has a Market Capitalization of 1489477760 and an Enterprise Value of 1412960640. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.59 while its Price-to-Book (P/B) ratio in mrq is 16.00. Its current Enterprise Value per Revenue stands at 6.391 whereas that against EBITDA is 3968.99.
Stock Price History:
The Beta on a monthly basis for AVDL is 1.46, which has changed by 0.19203746 over the last 52 weeks, in comparison to a change of 0.17342639 over the same period for the S&P500. Over the past 52 weeks, AVDL has reached a high of $16.66, while it has fallen to a 52-week low of $6.38. The 50-Day Moving Average of the stock is 7.23%, while the 200-Day Moving Average is calculated to be 47.72%.
Shares Statistics:
For the past three months, AVDL has traded an average of 1.28M shares per day and 1293680 over the past ten days. A total of 96.78M shares are outstanding, with a floating share count of 92.75M. Insiders hold about 4.48% of the company’s shares, while institutions hold 80.84% stake in the company. Shares short for AVDL as of 1757894400 were 10444932 with a Short Ratio of 8.14, compared to 1755216000 on 10122790. Therefore, it implies a Short% of Shares Outstanding of 10444932 and a Short% of Float of 12.560001000000002.
Earnings Estimates
. The current rating of Avadel Pharmaceuticals plc (AVDL) reflects the combined expertise of 7.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.1, with high estimates of $0.15 and low estimates of $0.07.
Analysts are recommending an EPS of between $0.34 and $0.17 for the fiscal current year, implying an average EPS of $0.23. EPS for the following year is $0.73, with 6.0 analysts recommending between $1.14 and $0.49.
Revenue Estimates
A total of 10 analysts believe the company’s revenue will be $73.58M this quarter.It ranges from a high estimate of $74.7M to a low estimate of $72.52M. As of. The current estimate, Avadel Pharmaceuticals plc’s year-ago sales were $50.02MFor the next quarter, 10 analysts are estimating revenue of $78.05M. There is a high estimate of $80.14M for the next quarter, whereas the lowest estimate is $73.85M.
A total of 10 analysts have provided revenue estimates for AVDL’s current fiscal year. The highest revenue estimate was $274.9M, while the lowest revenue estimate was $267.02M, resulting in an average revenue estimate of $272.27M. In the same quarter a year ago, actual revenue was $169.12MBased on 10 analysts’ estimates, the company’s revenue will be $356.12M in the next fiscal year. The high estimate is $378.3M and the low estimate is $333.7M.
